Compare Global E Online Ltd (GLBE) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Global E Online Ltd trades at $40.03 (market cap $6.54B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Global E Online Ltd is far larger — about 2.9× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Global E Online Ltd is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| GLBE | SLS | |
|---|---|---|
Market Cap | $6.54B | $2.28B |
Volume | 1,011,873 | 3,128,960 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $15.46 |
52-Week Low | $27.54 | $1.39 |
Typical Hold Time | 21 Days | — |
Enterprise Value | $6.04B | $2.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.96, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year outlook, with revenue growth of 39% year-over-year. Recent news includes the appointment of Tomer Gold as Chief Revenue Officer and significant insider selling by executives.
The outlook is positive with robust analyst support—93% buy ratings and a $48.86 consensus price target implying 25% upside. Key risks include insider selling pressure and execution challenges in maintaining high growth. Earnings growth and margin expansion remain primary catalysts for stock appreciation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
